Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD

• Status: Completed
• Trial end date: 2018-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The hypothesis is that in acute exacerbated Chronic Obstructive Pulmonary Disease (AECOPD), personalized variable dose glucocorticoid treatment will result in superior clinical outcome when compared to fixed dose therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cholinergic Agents; Glucocorticoids; Methylprednisolone; Muscarinic Antagonists

Criteria

Inclusion Criteria:

• Exacerbation of COPD as defined by the presence of at least 2 of the following: change in baseline dyspnea, cough, or sputum quantity or purulence.

Exclusion Criteria:

• Signs of severe exacerbation (arterial pH < 7.26 or PaCO2 > 9.3 kPa)

• History of asthma

• Significant or unstable co-morbidity

• Participated in another study 4 weeks before admission

• Previously randomized to this study

• Known hypersensitivity to prednisolone

• Inability to give written informed consent

• Radiological diagnosis of pneumonia

• Estimated survival of less than 6 months due to severe comorbidity

• Use of glucocorticoid within 1 month before admission